Literature DB >> 17159096

Differences in neuropathologic characteristics across the Lewy body dementia spectrum.

C Ballard1, I Ziabreva, R Perry, J P Larsen, J O'Brien, I McKeith, E Perry, D Aarsland.   

Abstract

BACKGROUND: The objective of this comparative neuropathologic study was to determine the extent to which dementia with Lewy bodies (DLB) and Parkinson disease dementia (PDD) are distinct entities or part of a continuum with respect to the duration of parkinsonism.
METHODS: We evaluated the relationship between cortical alpha-synuclein pathology, plaques (Consortium to Establish a Registry for Alzheimer's Disease [CERAD]), tangles (Braak staging), and cholinergic deficits (choline acetyltransferase in temporal cortex) in 57 prospectively assessed patients (29 DLB, 28 PDD), confirmed at autopsy. The PDD group was divided according to the median duration of parkinsonism prior to dementia.
RESULTS: There was an association between longer duration of parkinsonism prior to dementia and less severe cortical alpha-synuclein pathology (chi(2) 10.4, df 2, p = 0.006) and lower CERAD plaque scores (chi(2) 26.6, df 9, p = 0.002), but not Braak staging. These findings were confirmed in a further correlation analysis, which also identified an unexpected correlation between more pronounced cortical cholinergic deficits and longer duration of parkinsonism prior to dementia (R = -0.37, p = 0.04).
CONCLUSION: While there is a clear relationship between the duration of Parkinson disease prior to the onset of dementia and key neuropathologic and neurochemical characteristics, there is a gradation of these differences across the dementia with Lewy bodies/Parkinson disease dementia spectrum and the findings do not support an arbitrary cut-off between the two disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17159096     DOI: 10.1212/01.wnl.0000249130.63615.cc

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  89 in total

1.  Amyloid imaging of Lewy body-associated disorders.

Authors:  Erin R Foster; Meghan C Campbell; Michelle A Burack; Johanna Hartlein; Hubert P Flores; Nigel J Cairns; Tamara Hershey; Joel S Perlmutter
Journal:  Mov Disord       Date:  2010-11-15       Impact factor: 10.338

2.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

Review 3.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

4.  The impact of cerebrospinal fluid biomarkers on the diagnosis of Alzheimer's disease.

Authors:  Sebastiaan Engelborghs; Nathalie Le Bastard
Journal:  Mol Diagn Ther       Date:  2012-06-01       Impact factor: 4.074

5.  Past appendectomy may be related to early cognitive dysfunction in Parkinson's disease.

Authors:  Alexandra R Gonçalves; Alexandre Mendes; Nuno Vila-Chã; Joana Damásio; Joana Fernandes; Sara M Cavaco
Journal:  Neurol Sci       Date:  2020-06-11       Impact factor: 3.307

6.  Cognitive status correlates with white matter alteration in Parkinson's disease.

Authors:  Takaaki Hattori; Satoshi Orimo; Shigeki Aoki; Kenji Ito; Osamu Abe; Atsushi Amano; Ryo Sato; Kasumi Sakai; Hidehiro Mizusawa
Journal:  Hum Brain Mapp       Date:  2011-04-14       Impact factor: 5.038

7.  Neuropathologic substrates of Parkinson disease dementia.

Authors:  David J Irwin; Matthew T White; Jon B Toledo; Sharon X Xie; John L Robinson; Vivianna Van Deerlin; Virginia M-Y Lee; James B Leverenz; Thomas J Montine; John E Duda; Howard I Hurtig; John Q Trojanowski
Journal:  Ann Neurol       Date:  2012-10-04       Impact factor: 10.422

8.  Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study.

Authors:  Alexander V Lebedev; E Westman; M K Beyer; M G Kramberger; C Aguilar; Z Pirtosek; D Aarsland
Journal:  J Neurol       Date:  2012-12-08       Impact factor: 4.849

Review 9.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

10.  Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.

Authors:  Inger van Steenoven; Dag Aarsland; Daniel Weintraub; Elisabet Londos; Frédéric Blanc; Wiesje M van der Flier; Charlotte E Teunissen; Brit Mollenhauer; Tormod Fladby; Milica G Kramberger; Laura Bonanni; Afina W Lemstra
Journal:  J Alzheimers Dis       Date:  2016-08-18       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.